

**BUY** **Petronet LNG****Stock investible despite petchem foray; all eyes on QatarGas renewal** Your success is our success

Oil &amp; Gas ▶ Company Update ▶ December 14, 2023

**TARGET PRICE (Rs): 245**

**PLNG's Rs207bn petchem foray is difficult to quantify in terms of value add, but we do not foresee a washout and believe the stock is investible, going by its valuations and balance sheet. Sector outlook too is stable, with LNG prices under control. Renewal of the QatarGas deal (likely within 1-3 months) is a key event, as a 15-20-year extension would give long-term earnings visibility on core business, and factors like annual escalation in regas charge continuing are likely to be a significant trigger. In our SA model, we assume avg. core capex of Rs15bnpa and equity investment of Rs52bn in petchem, with nil contribution from the latter and Gopalpur; but even assuming full petchem capex in SA and Rs60bn from a land-based unit in Gopalpur, debt/equity would stay under 1x and even 70% DPR be maintainable. We cut TP by ~8% to Rs245; retain BUY.**

**Petronet LNG: Financial Snapshot (Standalone)**

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	4,27,376	5,90,504	5,02,507	5,25,065	5,38,354
EBITDA	48,213	40,069	47,543	48,991	51,513
Adj. PAT	30,294	25,461	32,163	33,876	35,214
Adj. EPS (Rs)	20.2	17.0	21.4	22.6	23.5
EBITDA margin (%)	11.3	6.8	9.5	9.3	9.6
EBITDA growth (%)	2.6	(16.9)	18.7	3.0	5.1
Adj. EPS growth (%)	13.7	(3.4)	(0.7)	5.3	4.0
RoE (%)	20.7	11.4	20.4	19.5	18.4
RoIC (%)	23.4	13.4	25.8	26.9	24.6
P/E (x)	10.4	12.4	9.8	9.3	8.9
EV/EBITDA (x)	5.9	7.2	6.0	5.7	5.3
P/B (x)	2.3	2.1	1.9	1.7	1.6
FCFF yield (%)	11.9	5.1	6.1	5.9	8.1

Source: Company, Emkay Research

**Petchem profitability cannot be quantified as of now, but washout unlikely**

PLNG's Rs206.9bn PDH-PP and ethane/propane handling capex can be viewed disapprovingly, given it is a new segment for the company (petchem, wherein PSUs have not been able to deliver so far) and adds global cyclical to an otherwise stable gas utility business. Even so, distinct advantages like Dahej location (home to multiple consumers), LT sale to Deepak Phenolics, cold-energy benefit and utility nature of C2-C3 handling (potential customers like OPaL & GAIL may be ready) are factors that can support profitability. We hence write off Rs52bn of pure PDH-PP equity only from the FV.

**Entering a heavy-capex phase, but balance-sheet or dividend stress unlikely**

We assume the subsidiary route for petchem, but if the entire capex is taken up by the SA entity, PLNG could see peak capex of Rs105bn in FY26E and FY24-28E cumulative of ~Rs300bn. This would impact FCF and valuations, but overall balance sheet would not be stressed, as over Rs70bn cash is already at hand. Even with 70% dividend payout, net D/E would peak out at ~0.8x (Rs150-160bn debt) during FY28-29E. We assume nil earnings from petchem and Gopalpur in our model and is hence a back-ended upside risk.

**QatarGas contract renewal a big event; can have a major bearing on valuation**

QatarGas term-contract renewal may grant long-term earnings visibility, and important elements like regas tariff & annual escalation rate, volume, slope and economics can have a material impact on PLNG's valuation. With most Indian LNG terminals pegged to Dahej, we do not expect a tariff reset, though annual hike may change from 5%; but even a 3% hike can be sizably positive, as for now we do not build any hike from FY28E.

**Sector outlook stable; we cut TP, taking a conservative stance; retain BUY**

Indian demand outlook is stable. With RIL's MJ gas field starting production, ONGC's 98/2 is the last of the domestic sources. A couple of LNG terminals are expected to be operative in the next one year, though we expect 6% gas demand CAGR and see demand-supply balancing out going ahead. We cut PLNG's TP by assigning no value to the petchem equity. Our FY24E/25E earnings, however, see only a minor change.

Target Price – 12M	Sep-24
<b>Change in TP (%)</b>	<b>(7.6)</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	16.9
CMP (13-Dec-23) (Rs)	209.8

Stock Data	Ticker
52-week High (Rs)	254
52-week Low (Rs)	192
Shares outstanding (mn)	1,500.0
Market-cap (Rs bn)	315
Market-cap (USD mn)	3,773
Net-debt, FY24E (Rs mn)	-30,563
ADTV-3M (mn shares)	5
ADTV-3M (Rs mn)	1,094.9
ADTV-3M (USD mn)	13.1
Free float (%)	50.0
Nifty-50	20,926
INR/USD	83.4
<b>Shareholding, Sep-23</b>	
Promoters (%)	50.0
FPIs/MFs (%)	33.3/5.9

**Price Performance**

(%)	1M	3M	12M
Absolute	6.2	(11.2)	(2.2)
Rel. to Nifty	(1.3)	(14.8)	(13.0)

**1-Year share price trend (Rs)****Sabri Hazarika**sabri.hazarika@emkayglobal.com  
+91 22 6612 1282**Harsh Maru**harsh.maru@emkayglobal.com  
+91 22 6612 1336**Arya Patel**arya.patel@emkayglobal.com  
+91 22 6612 1285

**Exhibit 1: PLNG announced that the PDH-PP and ethane-propane handling project cost is Rs206.85bn, of which PDH/handling is Rs136/25bn, though actual capex could be lower also**

Project cost	(Rs bn)
<b>Total</b>	<b>207</b>
PDH PP Hard Cost	136
Ethane Handling	25
Rupee Depreciation	19
IDC	16
Margin Money for working capital	4
Contingency+Others	7

Source: Company, Emkay Research

**Exhibit 2: PLNG’s 750ktpa PDH & 250/500ktpa propylene/PP project to cost ~Rs175bn, including soft costs, per our estimates**

Particulars	Value	Remark
Propane required (ktpa)	900	85% yield, as per management
Propylene production (ktpa)	250	Already tied up for sale to Deepak Phenolics for 15+5 years
PP production (ktpa)	500	Will sell in the market
Hydrogen production (ktpa)	~30	11ktpa already signed
Capex (Rs mn)	1,74,668	Revised from Rs130-140bn indicative earlier due to soft costs
Commissioning	Oct-27	Mechanical completion may be before that
Capex/ton (USD)	2,806	Similar to GAIL’s project in Usar, Roha (MH)

Source: Company, Emkay Research

**Exhibit 3: The Rs32bn (estimated) ethane & propane handling business could generate 11% RoCE, given its utility nature – Opal and GAIL Pata being potential customers**

Particulars	(Rs mn)
Bal. Capex (Ethane + Propane)	32,182
Revenue	5,100
<b>EBITDA</b>	<b>4,845</b>
Depreciation/Amortization	1,287
EBIT	3,558
Interest	1,802
<b>PAT</b>	<b>1,313</b>
Capacity (ktpa)	1,200
RoCE	11%
RoE	14%

Source: Company, Emkay Research

**Exhibit 4: The PDH-PP project is feasible on paper, though actual business predictability is low, as of now, as it is 4-5 years backended**

(Rs mn)	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E	FY31E	FY32E	FY33E	FY34E	FY35E
Capex	-26,200	-69,867	-52,401	-26,200	-1,747	-1,747	-1,747	-1,747	-1,747	-1,747	-1,747
Debt	18,340	67,247	1,03,928	1,22,268	1,22,268	1,11,768	99,768	86,768	72,768	58,768	42,768
Sales volume (ktpa)					622	778	778	778	778	778	778
Gross Delta/mt (USD)					484	484	484	484	484	484	484
EBITDA/mt (USD)					284	354	354	354	354	354	354
EBITDA					15,044	23,433	23,433	23,433	23,433	23,433	23,433
PAT					(1,759)	5,933	6,639	7,429	8,288	9,181	10,141
RoE					-3%	11%	11%	11%	11%	11%	11%
RoCE					5%	9%	9%	9%	9%	9%	9%

Source: Bloomberg, Emkay Research

**Exhibit 5: India PP demand-supply outlook is stable, with 7% CAGR likely, though more PP plants can unbalance it**

(mmtpa)	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E
Production	4.3	4.4	4.8	5.0	4.2	5.2	5.5	5.7	6.0	6.8	8.1	9.1	9.5	10.1
Consumption	4.5	4.7	4.9	5.4	4.9	5.8	6.2	6.8	7.4	8.0	8.6	9.1	9.5	10.0
Net Import	0.2	0.4	0.1	0.5	0.7	0.6	0.7	1.1	1.4	1.2	0.5	0.0	0.0	-0.1

Source: Company, GoI, Industry, Emkay Research

**Exhibit 6: Current PP capacities in India – RIL, the biggest player**

(mmtpa)	FY23	Location
RIL	3.0	Jamnagar
IOCL	0.6	Paradip
HMEL	0.5	Bhatinda
Haldia Petro	0.4	Midnapore
MRPL	0.4	Mangalore
OPaL	0.4	Dahej
BCPL	0.1	Dibrugarh
<b>Total</b>	<b>5.4</b>	


Source: Company, Industry, Emkay Research

**Exhibit 7: Upcoming PP capacities in India – Indian capacity expected to double by CY30**

Company	mmtpa	Completion	Location
Nayara	0.5	FY25	Vadinar refinery project
IOCL	1.2	FY25-26	Barauni, Gujarat, Panipat refinery expansion
GAIL	0.6	FY25-26	Usar PDH-PP & Pata small project
HRRL	1.0	FY26	Integrated Barmer refinery with 2mmtpa+ petchem
CPCL	0.5	FY27	CY basin refinery project
NRL	0.4	FY28	Numaligarh refinery project
PLNG	0.8	FY29	Dahej PDH-PP project
BPCL	0.4	FY30+	Kochi refinery (under planning)
<b>Total</b>	<b>5.2</b>		

Source: Company, Industry, Emkay Research

**Exhibit 8: PP intensity per capita in India remains low, as compared with the world average, thus propelling O&G companies towards the segment**



Source: World Bank, Emkay Research

**Exhibit 9: PLNG’s overall active capex plan is ~Rs400bn for the next 5 years, with Rs100bn PAT targeted annually thereafter**

(Rs mn)	Stated Capex	Completion	Remarks
Dahej - two tanks	12,500	Jun-24	
Dahej – regas expansion to 22.5mmtpa capacity	5,700	Mar-25	Operationalize by Apr-May '25
Dahej - third jetty	16,500	CY25 end	Awarding jobs now
Kochi - new tank	6,000		For flexibility (no recent update)
Additional truck loading in terminals	700		6 skids
Kochi - GUCD scheme	100		
Gopalpur - 4mmtpa FSRU terminal	23,060	CY25	Lease documents finalized by co. committee; would now be presented to the PLNG board for approval and submitted with the port authorities, followed by award of jobs. FSRU tender to be out soon
0.75mmtpa PDH PP & 1.2mmtpa ethane-propane handling	2,06,850	Early CY28	Board has approved PDH PP (0.25 propylene) and ethane & propane handling project; pre-project activities under way
New head office at Dwarka Delhi	1,500		40% physical progress as of end-FY23
Affordable housing complex	1,000	Feb-25	1,500 dwelling units under the scheme
LNG retail	80,000	Total	4 stations ready with IOCL; will go slow at 15-20 every 1.5 years, for Rs100-150mn capex each
CBG	40,000	Total	Have 4-5 units now, but land acquisition is a major issue due to which it will be slow; MOU signed with OIL
<b>Total</b>	<b>3,93,910</b>		


Source: Company, Emkay Research

**Exhibit 10: We estimate Rs312bn of cumulative capex during FY20-30 which could be Rs347bn if the Gopalpur terminal becomes land based**

(Rs mn)	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E	Cumulative
Total Capex	1,099	460	1,254	9,597	16,040	57,700	104,568	73,293	36,677	5,569	5,820	312,076
Ex Petchem Capex	1,099	460	1,254	8,627	15,340	26,350	20,968	10,593	5,327	5,569	5,820	101,406
Dahej - two Tanks			1,461	5,978	4,000	1,600						13,039
Dahej - 22.5mmtpa Regas				214	3,000	2,700	100					6,014
Dahej - 3rd Jetty					3,000	7,000	6,000	1,000				17,000
Gopalpur FSRU				2	500	10,000	10,000	4,500				25,002
Petchem PDH PP+C2-C3 Handling				971	700	31,350	83,600	62,700	31,350			210,671
New Office - Dwarka	12	194	200	294	400	400						1,500
LNG - Retail				500	1,440	1,500	1,560	1,620	1,680	1,740	1,800	11,840
Others (incl disposals)	1,087	266	-407	1,638	3,000	3,150	3,308	3,473	3,647	3,829	4,020	27,011
Gopalpur, if land-based							9,000	24,000	18,000	9,000		60,000
Total Capex (land-based Gopalpur)	1,099	460	1,254	9,595	15,540	47,700	103,568	92,793	54,677	14,569	5,820	347,074


Source: Company, Emkay Research

**Exhibit 11: Net debt-to-equity to remains comfortable at 0.8x peak level, assuming entire petchem capex in standalone & dividend payout being hiked to 70% vs 50% currently**



Source: Company, Emkay Research

**Exhibit 12: PLNG’s dividend yield would be attractive at 8-9%, assuming 70% pay-out ratio in the forecast period**




Source: Company, Emkay Research

**Exhibit 13: QatarGas term LNG contract renewal a major event for valuations; we do not foresee any downside**

Scenario	TP (Rs)	Assumptions
Base	245	Assuming explicit period up to FY37 and then TV with 0% TvG, no Gopalpur, LNG retail or petchem contribution
Bear	225	Same as above, but extension of DCF till FY50 (contract extending by 20 years) with nil TV but 10% of gross block & net current assets as residual value
Bull	285	Same as above, but with 2.5% annual escalation in Dahej and the Kochi regas tariff over the long term


Source: Emkay Research

**Exhibit 14: Indian gas demand-supply outlook – Demand slated to clock 6% CAGR over FY23-30E, driven by refineries, petchem and CGD**



Source: Company, GoI, Industry, Emkay Research

**Exhibit 15: Current gas prices point to a stable medium-term outlook; supplies expected to be comfortable**



Source: Bloomberg, Emkay Research

**Exhibit 16: Change in assumptions – Slight change in spot marketing margin assumed**

	FY24E			FY25E			FY26E
	Previous	Revised	Variance	Previous	Revised	Variance	Introduced
EBITDA/mmbtu (Rs)	51.4	51.5	0%	52.4	51.1	-2%	52.1
Blended Regas Tariff (Rs/mmbtu)	70.2	68.7	-2%	73.5	71.9	-2%	72.1
Volumes (mmt)	17.7	18.1	2%	18.8	18.8	0%	19.4
Growth	20%	23%	298bps	6%	4%	-189bps	3%

Source: Emkay Research

**Exhibit 17: Change in estimates; minor changes in operating profit estimates**

(Rs bn)	FY24E			FY25E			FY26E
	Previous	Revised	Variance	Previous	Revised	Variance	Introduced
Revenue	571.4	502.5	-12%	566.9	525.1	-7%	538.4
EBITDA	46.5	47.5	2%	50.1	49.0	-2%	51.5
EBITDA margin	8.1%	9.5%	133bps	8.8%	9.3%	49bps	9.6%
PAT	30.9	32.2	4%	34.2	33.9	-1%	35.2
EPS (Rs)	20.6	21.4	4%	22.8	22.6	-1%	23.5

Source: Emkay Research

**Exhibit 18: DCF-based valuation (Sep-24E)**

DCF Assumptions		(Rs.mn)
Risk Free Rate	7.0%	NPV Of FCF (Sep'25-Sep'36)
Risk Premium	5.3%	Terminal Value
Beta	0.8	PV Of TV
Cost Of Equity	11.0%	Total Value
Cost Of Debt	9.0%	Less: Adj. Net Debt (Y/E)
Post Tax Cost Of Debt	6.7%	<b>Equity Value</b>
Average Debt:Equity Ratio	0.0%	No. Of Shares O/S (mn)
<b>WACC</b>	<b>11.0%</b>	<b>Target Price (Rs.)</b>
Terminal Growth Rate	0.0%	


Source: Emkay Research

**Exhibit 19: P/E-based valuation (Sep-25E) – Stock trades at ~9x currently**

(Rs)	FY21	FY22	FY23	FY24E	FY25E	FY26E
EPS	19.7	20.2	17.0	21.4	22.6	23.5
Implied Target Multiple (x)						10.6
<b>DCF Target Price per share</b>						<b>245</b>

Source: Company, Emkay Research

**Exhibit 20: P/E valuation band – One-year forward**



Source: Company, Bloomberg, Emkay Research

## Petronet LNG: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Revenue</b>	<b>4,27,376</b>	<b>5,90,504</b>	<b>5,02,507</b>	<b>5,25,065</b>	<b>5,38,354</b>
Revenue growth (%)	64.2	38.2	(14.9)	4.5	2.5
<b>EBITDA</b>	<b>48,213</b>	<b>40,069</b>	<b>47,543</b>	<b>48,991</b>	<b>51,513</b>
EBITDA growth (%)	2.6	(16.9)	18.7	3.0	5.1
Depreciation & Amortization	7,685	7,643	7,700	7,788	9,093
<b>EBIT</b>	<b>40,529</b>	<b>32,425</b>	<b>39,843</b>	<b>41,203</b>	<b>42,420</b>
EBIT growth (%)	3.5	(20.0)	22.9	3.4	3.0
Other operating income	0	0	0	0	0
Other income	3,073	4,943	6,133	7,391	8,304
Financial expense	3,173	3,305	2,977	3,306	3,646
<b>PBT</b>	<b>40,428</b>	<b>34,063</b>	<b>42,998</b>	<b>45,289</b>	<b>47,078</b>
Extraordinary items	4,310	9,282	0	0	0
Taxes	11,215	10,946	10,836	11,413	11,864
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>33,524</b>	<b>32,399</b>	<b>32,163</b>	<b>33,876</b>	<b>35,214</b>
PAT growth (%)	13.7	(3.4)	(0.7)	5.3	4.0
<b>Adjusted PAT</b>	<b>30,294</b>	<b>25,461</b>	<b>32,163</b>	<b>33,876</b>	<b>35,214</b>
<b>Diluted EPS (Rs)</b>	<b>20.2</b>	<b>17.0</b>	<b>21.4</b>	<b>22.6</b>	<b>23.5</b>
Diluted EPS growth (%)	13.7	(3.4)	(0.7)	5.3	4.0
<b>DPS (Rs)</b>	<b>11.5</b>	<b>10.0</b>	<b>10.7</b>	<b>11.3</b>	<b>11.7</b>
<b>Dividend payout (%)</b>	<b>51.5</b>	<b>46.3</b>	<b>50.0</b>	<b>50.0</b>	<b>50.0</b>
EBITDA margin (%)	11.3	6.8	9.5	9.3	9.6
EBIT margin (%)	9.5	5.5	7.9	7.8	7.9
Effective tax rate (%)	35.7	52.5	25.2	25.2	25.2
<b>NOPLAT (pre-IndAS)</b>	<b>26,048</b>	<b>15,401</b>	<b>29,802</b>	<b>30,820</b>	<b>31,730</b>
Shares outstanding (mn)	1,500.0	1,500.0	1,500.0	1,500.0	1,500.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	40,428	34,063	42,998	45,289	47,078
Others (non-cash items)	9,266	10,176	4,544	3,703	4,435
Taxes paid	(12,642)	(12,380)	(12,122)	(12,712)	(13,176)
Change in NWC	(6,641)	(15,943)	31	(1,638)	(1,218)
<b>Operating cash flow</b>	<b>34,721</b>	<b>25,199</b>	<b>35,452</b>	<b>34,641</b>	<b>37,119</b>
Capital expenditure	(723)	(10,577)	(18,000)	(18,000)	(15,000)
Acquisition of business	0	0	0	0	0
Interest & dividend income	2,186	2,952	6,133	7,391	8,304
<b>Investing cash flow</b>	<b>7,230</b>	<b>(7,984)</b>	<b>(11,956)</b>	<b>(21,177)</b>	<b>(22,505)</b>
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(6,271)	(6,177)	2,200	4,500	7,800
Payment of lease liabilities	(2,772)	(2,772)	(2,772)	(2,772)	(2,772)
Interest paid	(88)	(253)	(2,977)	(3,306)	(3,646)
Dividend paid (incl tax)	(15,750)	(17,250)	(16,081)	(16,938)	(17,607)
Others	0	0	0	0	0
<b>Financing cash flow</b>	<b>(22,109)</b>	<b>(23,681)</b>	<b>(16,858)</b>	<b>(15,744)</b>	<b>(13,453)</b>
Net chg in Cash	19,842	(6,465)	6,637	(2,280)	1,161
OCF	34,721	25,199	35,452	34,641	37,119
Adj. OCF (w/o NWC chg.)	41,362	41,142	35,420	36,279	38,337
FCFF	33,998	14,622	17,452	16,641	22,119
FCFE	33,010	14,268	20,608	20,726	26,777
OCF/EBITDA (%)	72.0	62.9	74.6	70.7	72.1
FCFE/PAT (%)	98.5	44.0	64.1	61.2	76.0
<b>FCFF/NOPLAT (%)</b>	<b>130.5</b>	<b>94.9</b>	<b>58.6</b>	<b>54.0</b>	<b>69.7</b>

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	15,000	15,000	15,000	15,000	15,000
Reserves & Surplus	1,19,255	1,34,347	1,50,429	1,67,367	1,84,974
<b>Net worth</b>	<b>1,34,255</b>	<b>1,49,347</b>	<b>1,65,429</b>	<b>1,82,367</b>	<b>1,99,974</b>
Minority interests	0	0	0	0	0
Deferred tax liability (net)	8,324	7,031	5,744	4,445	3,132
<b>Total debt</b>	<b>43,721</b>	<b>40,874</b>	<b>43,408</b>	<b>48,246</b>	<b>56,387</b>
<b>Total liabilities &amp; equity</b>	<b>1,86,300</b>	<b>1,97,252</b>	<b>2,14,581</b>	<b>2,35,057</b>	<b>2,59,493</b>
Net tangible fixed assets	95,570	87,901	81,501	83,013	1,06,720
Net intangible assets	2	2	2	2	2
Net ROU assets	27,076	27,076	27,076	27,076	27,076
Capital WIP	1,926	11,259	27,959	36,659	18,859
Goodwill	0	0	0	0	0
Investments [JV/Associates]	1,744	1,748	1,750	12,230	27,950
<b>Cash &amp; equivalents</b>	<b>72,024</b>	<b>65,497</b>	<b>72,222</b>	<b>70,030</b>	<b>71,280</b>
Current assets (ex-cash)	39,925	57,819	54,333	57,242	59,326
Current Liab. & Prov.	24,891	26,974	23,185	24,118	24,643
<b>NWC (ex-cash)</b>	<b>15,034</b>	<b>30,845</b>	<b>31,148</b>	<b>33,124</b>	<b>34,683</b>
<b>Total assets</b>	<b>1,86,300</b>	<b>1,97,252</b>	<b>2,14,581</b>	<b>2,35,057</b>	<b>2,59,493</b>
Net debt	(30,046)	(26,372)	(30,563)	(34,014)	(42,843)
Capital employed	1,86,300	1,97,252	2,14,581	2,35,057	2,59,493
<b>Invested capital</b>	<b>1,10,606</b>	<b>1,18,748</b>	<b>1,12,651</b>	<b>1,16,139</b>	<b>1,41,405</b>
BVPS (Rs)	89.5	99.6	110.3	121.6	133.3
Net Debt/Equity (x)	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)
Net Debt/EBITDA (x)	(0.6)	(0.7)	(0.6)	(0.7)	(0.8)
Interest coverage (x)	0.1	0.1	0.1	0.1	0.1
<b>RoCE (%)</b>	<b>24.4</b>	<b>19.5</b>	<b>22.3</b>	<b>21.6</b>	<b>20.5</b>

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	10.4	12.4	9.8	9.3	8.9
P/CE(x)	9.3	13.2	7.9	7.6	7.1
P/B (x)	2.3	2.1	1.9	1.7	1.6
EV/Sales (x)	0.7	0.5	0.6	0.5	0.5
EV/EBITDA (x)	5.9	7.2	6.0	5.7	5.3
EV/EBIT(x)	7.0	8.9	7.1	6.8	6.4
EV/IC (x)	2.6	2.4	2.5	2.4	1.9
FCFF yield (%)	11.9	5.1	6.1	5.9	8.1
FCFE yield (%)	10.5	4.5	6.5	6.6	8.5
Dividend yield (%)	5.5	4.8	5.1	5.4	5.6
<b>DuPont-RoE split</b>					
Net profit margin (%)	6.1	2.7	6.4	6.5	6.5
Total asset turnover (x)	2.4	3.1	2.4	2.3	2.2
Assets/Equity (x)	1.4	1.4	1.3	1.3	1.3
<b>RoE (%)</b>	<b>20.7</b>	<b>11.4</b>	<b>20.4</b>	<b>19.5</b>	<b>18.4</b>
<b>DuPont-RoIC</b>					
NOPLAT margin (%)	6.1	2.6	5.9	5.9	5.9
IC turnover (x)	0.0	0.0	0.0	0.0	0.0
<b>RoIC (%)</b>	<b>23.4</b>	<b>13.4</b>	<b>25.8</b>	<b>26.9</b>	<b>24.6</b>
<b>Operating metrics</b>					
Core NWC days	13.2	20.0	22.5	22.5	22.6
<b>Total NWC days</b>	<b>13.2</b>	<b>20.0</b>	<b>22.5</b>	<b>22.5</b>	<b>22.6</b>
Fixed asset turnover	3.4	4.9	4.2	4.2	3.7
Opex-to-revenue (%)	2.0	1.8	1.6	2.2	2.3


Source: Company, Emkay Research

**RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Nov-23	203	265	Buy	Sabri Hazarika
01-Aug-23	234	265	Buy	Sabri Hazarika
04-May-23	227	265	Buy	Sabri Hazarika
21-Jan-23	223	260	Buy	Sabri Hazarika
10-Nov-22	213	260	Buy	Sabri Hazarika
06-Aug-22	216	260	Buy	Sabri Hazarika
13-May-22	206	255	Buy	Sabri Hazarika
11-Feb-22	224	270	Buy	Sabri Hazarika
23-Nov-21	224	275	Buy	Sabri Hazarika
10-Nov-21	235	275	Buy	Sabri Hazarika
17-Aug-21	224	270	Buy	Sabri Hazarika
26-Jul-21	219	290	Buy	Sabri Hazarika
23-Jun-21	231	290	Buy	Sabri Hazarika
10-Jun-21	233	290	Buy	Sabri Hazarika
29-May-21	241	340	Buy	Sabri Hazarika
23-Apr-21	235	340	Buy	Sabri Hazarika
23-Mar-21	230	340	Buy	Sabri Hazarika
12-Feb-21	242	340	Buy	Sabri Hazarika
21-Jan-21	246	300	Buy	Sabri Hazarika

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative’s may have Financial Interest/proprietary positions in the securities recommended in this report as of December 14, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s may have material conflict of interest in the securities recommended in this report as of December 14, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative’s may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the December 14, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.